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Background: Poly(L-γ-glutamylglutamine) paclitaxel (PGG-PTX) conjugate is a non-diblock 
polymeric drug nanoparticle intended to improve the therapeutic index of paclitaxel. The purpose 
of the present study was to elucidate further the physicochemical properties of PGG-PTX in 
order to proceed with its clinical development.
Methods and results: PGG-PTX was designed by integration of a hydrophobic paclitaxel 
conjugate through an added hydrophilic glutamic acid onto poly(L-glutamic acid). The addition 
of a flexible glutamic linker between PGA and paclitaxel resulted in spontaneous self-assembly 
of a PGG-PTX conjugate into nanoparticles. The PGG-PTX conjugate was stable as a lyophilized 
solid form. An in vitro viability experiment showed that PGG-PTX was effective after a longer 
incubation period, the same trend as Taxol. In vitro studies using NCI-H460 and B16F0 cancer 
cells demonstrated significantly high cellular uptake after 30 minutes of incubation. The in 
vivo biocompatibility of PGG-PTX conjugate was evaluated in the NCI-H460 tumor model, 
the assessment of tissue seemed to be normal after 21 days of treatment.
Conclusion: These results are encouraging for further development of non-block polymeric 
paclitaxel nanoparticles for treatment of cancer.
Keywords: polymer conjugate, paclitaxel, poly(L-γ-glutamylglutamine), drug delivery, 
physicochemical properties, nanoparticles
Introduction
Conventional small-molecule cancer chemotherapy has a low therapeutic index 
due to poor aqueous solubility, the inability to target tumor tissues selectively, and 
multidrug resistance.1 A number of technologies have been explored to increase 
water solubility and tumor selectivity, and to overcome the drug resistance of these 
anticancer drugs. Nanoparticulate technologies can be used to improve water solubility 
and bioavailability.2 Examples of such technologies include nanocrystal drug particles, 
nanocrystal/amorphous drugs stabilized with compatible carriers, micronanoparticulate/
water droplet drug stabilized by phospholipids, calcium phosphate-based nanoparticles, 
and injectable suspensions of nanoparticle albumin-bound technology, as well 
as microprecipitation, lipid emulsion, and disperse-phase technology. Polymer 
nanotherapeutics offer another route for improving water solubility, tumor selectivity, 
and drug resistance.3–5 A polymer-drug conjugate comprises three components, ie, a 
suitable polymeric carrier, a biodegradable linker, and a bioactive antitumor agent. 
A macromolecular polymeric conjugate is intended to prolong the circulation time by 
avoiding kidney filtration and to target tumors passively by the “enhanced permeability International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and retention” effect, attributed to discontinuous endothelium 
in the tumor vasculature and poor lymphatic tumor 
drainage.6
Like many other hydrophobic anticancer drugs, 
  paclitaxel7 is hindered by poor bioavailability because 
of its low solubility in aqueous solution and lack of 
tumor selectivity. Nonetheless, paclitaxel formulated in a 
Cremophor EL® and ethanol mixture has been approved by 
the US Food and Drug Administration to treat patients with 
ovarian, breast, lung, and head and neck cancer, and advanced 
forms of Kaposi’s sarcoma. The mixture of   Cremophor 
EL and ethanol8 can solubilize paclitaxel at a 6 mg/mL 
concentration for infusion. Emulsification of paclitaxel has 
also been investigated using high-shear homogenization to 
improve its water solubility.9 Paclitaxel conjugated with a   
water-soluble polymer has recently been reported. Polymer-
paclitaxel conjugates have been advanced in several clinical 
trials.10 The poly(L-glutamic acid)-paclitaxel conjugate 
(CT-2103) is considered the most advanced polymer-
paclitaxel conjugate to date.4 CT-2103 has been investigated 
in Phase III trials, but has not been approved as yet by the 
Food and Drug Administration,11–13 so there is still a need for 
an efficacious polymer-paclitaxel conjugate for the treatment 
of cancer.
In an attempt to improve the pharmacological profile of 
paclitaxel, poly(L-γ-glutamylglutamine)-paclitaxel (PGG-
PTX) was designed as a polymer-drug conjugate. We have 
reported the preparation of PGG-PTX previously.14 Poly(L-
γ-glutamylglutamine) contains double carboxyl groups for 
drug attachment as compared with one carboxyl group on 
the parent chain, polyglutamic acid, which provides adequate 
carrying capacity for paclitaxel, with a high probability 
of it being water-soluble. The resulting PGG-PTX has a 
macromolecular weight of approximately 80 kDa, which 
would be beneficial for retention in the circulation and 
for accumulation in tumors.15 Linkage of paclitaxel to the 
poly(L-γ-glutamylglutamine) backbone markedly alters its 
urinary and fecal excretion behavior. In a preclinical tumor 
growth regression study, PGG-PTX was administered 
intravenously via the tail vein in a mouse model of NCI-H460 
carcinoma, 2008 human ovarian cancer, and B16F0, and the 
results showed that PGG-PTX outperformed protein-bound 
paclitaxel (Abraxane®) with respect to inhibition of tumor 
growth when both drugs were given at doses that produced 
similar degrees of acute weight loss.16 The purpose of the 
present study was to elucidate further the physicochemical 
properties of PGG-PTX in order to proceed with its clinical 
development. To this end, we confirmed the nanoparticle 
morphology of PGG-PTX by transmission electron 
microscopy (TEM) and investigated the long-term stability 
of lyophilized PGG-PTX at room temperature and at 4°C 
by determining its particle size and release of free paclitaxel 
from PGG-PTX. We also compared its in vitro cytotoxicity 
in various cancer cell lines and studied its cellular uptake. 
Histology studies did not reveal any tissue irregularities in 
NCI-H460-bearing mice after administration of the maximum 
tolerated dose of PGG-PTX. The results showed that PGG-
PTX was a sufficiently stable and biocompatible non-diblock 
nanoparticulate prodrug. In this study, we presented novel 
data of cellular uptake of PGG-PTX and in vitro potency 
of five more cancer cell lines: C6 glioma, A549 lung, Hela 
kidney, Caco-2 colon, and HepG2 liver cancer cell lines. 
The novelty also included the assessment of in vivo tissue 
biocompatibility in the NCI-H460 tumor model.
Materials and methods
reagents and cell lines
PGG-PTX was synthesized as described previously by our 
laboratory.14 Coumarin 6 was purchased from Sigma-Aldrich 
(St Louis, MO). Purified deionized water was prepared using 
the Milli-Q Plus system from Millipore Co (Bedford, MA). 
NCI-H460 cells were maintained in RPMI 1640 supplemented 
with 10% fetal bovine serum containing 100 U/mL penicillin 
and 100 µg/mL streptomycin. C6, A549, B16F0, and HepG2 
cell lines were maintained in Dulbecco’s modified Eagle’s 
medium with the same supplements. The Caco-2 cell line 
was grown in modified Eagle’s medium supplemented with 
10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 1% sodium pyruvate.
Physicochemical properties of Pgg-PTX
Pgg-PTX morphology
The shape and surface morphology of PGG-PTX were 
investigated by TEM (JEM-2100, JEOL, Peabody, MA). 
A layer of the PGG-PTX polymer powder was obtained 
and deposited on a copper grid for TEM by application of 
0.01% phosphotungstic acid after the PGG-PTX nanoparticle 
  suspension was air-dried.
size measurements
Samples of PGG-PTX were stored at 4°C and at room 
temperature for three months, and then tested for changes 
in particle size and size distribution within this time 
period. PGG-PTX sample was dissolved in phosphate-
buffered solution (pH 6.5) and 45% methyl alcohol buffer 
at a concentration of 2 mg/mL. Particle size was measured International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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using a Malvern Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK). Analysis of each PGG-PTX analytical 
solution was performed in triplicate. An 850 µL sample 
of solution was transferred to a Malvern disposable zeta 
cell with a 10 mm optical path for each measurement. For 
each PGG-PTX sample, the average volume diameter (nm) 
and polydispersity index were recorded. In addition, the 
experimental error for each parameter was recorded as the 
standard deviation.
stability experiments
The same samples used for the size measurements were 
analyzed for free paclitaxel using size-exclusion high-pressure 
liquid chromatography methods to determine the stability 
of the polymer-paclitaxel conjugate. Chromatographic 
separations were carried out using a Shodex® OHpak SB-804 
column (30 cm × 6.0 mm, 10 µm particle size) with a Shodex 
OHpak SB-G guard column (5 cm × 6.0 mm, 10 µm particle 
size) from Showa Denko KK, Tokyo, Japan. The mobile 
phase was a solution of methanol-phosphate buffer (pH 6.5, 
45: 55, v/v) at a flow rate of 0.525 mL/minute. The detection 
wavelength was carried out at λ 228 nm. The free amount of 
paclitaxel in the polymer was determined based on a standard 
curve for free paclitaxel.
Thermogravimetric differential thermal analysis
Thermal analyses were carried out using an SDT Q600 V8.3 
Build 101 thermogravimetric differential thermal analyzer. 
The procedure was adapted from a previous published 
method.17 Briefly, known quantities of paclitaxel and PGG-
PTX were transferred to aluminum pans. The pans were 
crimped and weighed. Heat was applied between 30°C 
and 500°C at a scanning rate of 5°C/minute in a nitrogen 
atmosphere.
cell culture
cellular uptake of coumarin 6-labeled Pgg-PTX 
nanoparticles
For visualizing the cellular uptake studies, coumarin 
6-labeled PGG-PTX nanoparticles were prepared based 
on a published method18 with a minor modification of 
changing the polymer. Briefly, NCI-H460 cells were cul-
tured on polylysine-coated glass cover slips. Aliquots of 
coumarin 6-loaded PGG-PTX nanoparticles (1.0 mg/mL) 
were   dispersed on glass slides and covered with coverslips. 
The cells were washed three times with phosphate-buffered 
solution after incubation for 30 minutes and 4 hours. The 
nuclei were then counterstained by DAPI for 15   minutes. 
Cellular uptake was visualized using a fluorescence 
microscope system (Olympus, Japan).
Quantitative cellular uptake of coumarin 6-labeled 
Pgg-PTX nanoparticles
For quantitative cellular uptake studies, the coumarin 
6-  labeled PGG-PTX nanoparticles were dispersed in medium 
at concentrations of 1.25, 2.5, 5, and 10 mg/mL, and each 
concentration was incubated independently with NCI-H460 
and B16F0 cells at 37°C. The cells were washed three times 
with 100 µL of phosphate-buffered solution after incubation 
for 0.5, 1, 2, and 4 hours. Lysis buffer (0.5% Triton X-100) 
was then added to the cells. Cell-associated fluorescence 
intensity from the coumarin 6-loaded nanoparticles was 
measured using a microplate reader (SpectraMax® M5) at 
an excitation wavelength of 430 nm and an emission wave-
length of 485 nm.
In vitro cytotoxicity assay
For cytotoxicity measurements, 100 µL of cell suspension in 
culture medium at a concentration of 3 × 104 cells/mL was 
seeded in each well of a 96-well plate, and incubated at 37°C 
in a humidified atmosphere with 5% CO2. After overnight 
incubation, serial dilutions of PGG-PTX were added to the 
plate. After further incubation for 48 or 72 hours, the cells 
were stained with standard MTS. Absorbance at 490 nm 
was measured with a microplate reader (Thermo Multiskan 
MK3). Cell viability was calculated as the absorbance 
in wells of treated cells normalized to controls, and the 
concentration of drug that inhibited cell viability by 50% 
(IC50) was determined.
Biocompatibility
hemolysis test
Hemolysis studies were carried out according to a published 
procedure.19 Briefly, red blood cells was freshly collected 
from a healthy male Sprague-Dawley rat and washed three 
times with 1× D-phosphate-buffered solution (pH 7.4) by 
centrifugation at 850 g for 15 minutes until the supernatant 
became clear. The red blood cells were adjusted to a density 
at 1 × 108 cells/mL with 1× phosphate-buffered solution 
(pH 7.4) and an aliquot (180 µL) of the suspension was added 
to each well of a round-bottom 96-well plate. Each testing 
material in phosphate-buffered solution (20 µL) was added 
to each corresponding well. Triton X-100 (0.2%) was used 
to generate 100% cell lysis as a positive control. The cells 
were incubated with the testing materials at 37°C for one hour 
on a three-dimensional rotation platform. After incubation, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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100 µL of supernatant was transferred to a new flat-bottom 
96-well plate after centrifuge at 850 g for 15 minutes. The 
hemoglobin released from the lysed red blood cells was 
measured by spectrophotometry at 541 nm. The data are 
presented as the mean of triplicate experiments (% relative to 
0.2% Triton X-100 treatment). The remaining red blood cell 
pellet from the centrifugation was gently resuspended and red 
blood cell aggregation was monitored by microscopy.
histology study using hematoxylin and eosin staining
To induce NCI-H460 tumors, nu/nu mice purchased from 
Vital River Laboratories (Beijing, China) were injected with 
4 × 106 NCI-H460 cells in medium over each shoulder as 
previously reported.15 The nu/nu mice were randomly divided 
into two groups. One group comprised the experimental sub-
jects, and the other group comprised controls. All the mice 
then received PGG-PTX at the maximum tolerated dose as 
described previously16 via tail vein injection when tumor 
size was about 100 mm3. After 21 days of treatment, various 
tissue samples were harvested. Tissue blocks were sectioned 
at a 5 µm thickness and placed on plain slides. The slides 
were deparaffinized in xylene and rehydrated through graded 
alcohols. They were then stained in Harris hematoxylin for 
four minutes and rinsed in tap water for two minutes. Next, 
they were differentiated in 1% acid alcohol, rinsed in distilled 
H2O, and stained blue in 1% ammonia alcohol. The slides 
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Figure 1 structure of paclitaxel and Pgg-paclitaxel conjugate. 
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Figure 2 Thermogravimetric/differential thermal analyzer curve of free paclitaxel (A) and polymer Pgg-PTX conjugate (B) with weight percent plotted against temperature. 
Abbreviations: PTX, paclitaxel; Pgg, poly(l-γ-glutamylglutamine); TgA, thermogravimetric analysis; DTA, differential thermal analysis.
were then placed sequentially in 70% ethanol, 95% ethanol, 
eosin, 100% ethanol, and xylene for one minute each. The 
slides were mounted with Permount.
statistical analysis
Data are expressed as the mean with 95% confidence 
intervals. Statistical tests were performed using the Student’s 
t-test. The tests were considered to be statistically significant 
when P values were less than 0.05. All the statistical tests 
used the two-tailed method.
Results and discussion
The main aim of this study was to evaluate the physico-
chemical properties, in vitro potency, and in vivo tissue 
and blood biocompatibility of an anticancer PGG-PTX 
conjugate. Detailed study of its properties is essential if 
PGG-PTX is to proceed to clinical development. The PGG-
PTX conjugate was proposed because the conjugate should 
be able to improve the therapeutic index of paclitaxel. 
  Previously, we have reported the synthesis of PGG-PTX 
and its in vitro cytotoxicity in a human lung NCI-460 cell 
line,14 its in vivo efficacy in a mouse model,16 and its   superior 
pharmacokinetics and biodistribution in a human lung NCI-
H460 mouse model.15 In the present study, the physicochemi-
cal properties, morphology, and stability of PGG-PTX were 
examined. Subsequently, cell viability assays were performed 
to investigate the antiproliferative activity of the PGG-PTX 
conjugate in various cancer cell lines. Further, fluorescence 
microscopy assays were carried out for some of the cells 
pretreated with fluorescence-loaded carriers to elucidate 
the internalization capacity of the polymer drug delivery 
systems. Hemolysis and aggregation of PGG-PTX and 
poly(L-γ-glutamylglutamine) was investigated to determine   
their biocompatibility. Finally, the tissue histology study 
indicated that PGG-PTX did not have any detrimental effect 
on tissue integrity.
characterization of Pgg-PTX conjugate
PGG-PTX was synthesized as previously reported,14 and its 
structure is shown in Figure 1. The synthesis of PGG-PTX 
started with poly(L-glutamate) sodium salt coupled with 
glutamic acid, followed by conjugation with paclitaxel in 
the presence of 4-dimethylaminopyridine catalysis. This 
modification makes it possible to form stable nanoparticles 
of PGG-PTX alone without any additive and other polymer 
or lipid. The amphiphilic structure of PGG-PTX comprises 
hydrophobic paclitaxel and a hydrophilic polar carboxylate 
portion. Its bulky structure and large surface area makes 
it an excellent emulsifier, solubilizer, and functional 
50 nm
Figure 3 Transmission electron micrograph of poly(l-γ-glutamylglutamine)-paclitaxel 
nanoconjugates.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  carrier for hydrophobic drugs. The paclitaxel-conjugated 
  content of PGG-PTX was determined to be 36% (weight 
by weight) using an ultraviolet method.14,20 The ratios of 
the carboxyl groups to paclitaxel and the ratios of glutamic 
acid units to paclitaxel were calculated to be about 10:1 and 
5:1, respectively, which might account for the high water 
solubility of the polymer (.50 mg/mL).
The thermal stability of the PGG-PTX polymer was 
identified by thermogravimetric analysis and differential 
thermal analysis. The initial mass of the material subjected to 
analysis was about 10.0 mg. The thermogravimetric analysis 
and differential thermal analysis curves are shown in Figure 2. 
The thermogravimetric analysis curve showed dehydration 
at 105°C and a moisture content of 11.7% gravimetrically 
evaluated for the PGG-PTX conjugate and 0.8% for free 
paclitaxel. This high water content for PGG-PTX results from 
the hygroscopic carboxylate group in the PGG backbone. 
Differential thermal analysis thermograms revealed one 
endothermic peak at 220°C and another exothermic peak 
at 236°C for free paclitaxel (Figure 2A). The former was 
the melting temperature, and the latter was assigned to 
decomposition. In the region between 210°C and 300°C, 
the endothermic peak seen in differential thermal analysis 
(Figure 2B) can be ascribed to the absorption of energy for 
the breaking of bonds at the initial stage of decomposition. 
These blunt endothermic and exothermic peaks indicate an 
amorphous sample, which is consistent with the literature 
published for polymers like PLGA and PLA.21,22
PGG-PTX has previously demonstrated a capacity for 
self-assembly in aqueous solution, forming nanoparticles 
of average size distribution at about 20 nm by dynamic 
light scattering14 as well as by modeling.23 In this study, 
a TEM image of PGG-PTX provided conclusive evidence 
that PGG-PTX did indeed form nanoparticles, and the 
particle sizes seemed to be consistent with previously 
reported results for dynamic light scattering14 and TEM.24 
As shown in Figure 3, the PGG-PTX nanoparticles were of 
a regular spherical shape, with a relatively homogeneous 
size distribution. In addition, the nanoparticle size of 
PGG-PTX in solution did not seem to have any significant 
effect with a change of pH from 7.1 to 5.5 or by time, for 
at least 24 hours at ambient temperature (data not shown). 
It is generally accepted that 20 nm nanoparticles would be 
ideal for evading the reticuloendothelial system and kidney 
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Figure 5 Fluorescence microscopy images showing internalization of NcI-h460 cell 
treated with coumarin 6-labeled poly(l-γ-glutamylglutamine)-paclitaxel nanoparticles 
(1  mg/mL)  at  37°c  for  30  minutes  and  4  hours.  On  the  left,  the  green-labeled 
corresponds  to  fluorescent  poly(l-γ-glutamylglutamine)-paclitaxel  loaded  with 
coumarin 6. On the right, merged images of the nuclei stained with DAPI (blue) and of 
the cells uptake of coumarin 6-loaded poly(l-γ-glutamylglutamine)-paclitaxel (green). 
Notes:  The  results  are  representative  of  three  independent  experiments. 
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In vitro cellular proliferation and uptake 
studies in tumor cell lines
Clearly, the cellular uptake efficiency of a polymer-drug 
conjugate affects its therapeutic properties. To study the cel-
lular uptake of nonfluorescent PGG-PTX, we adapted a pub-
lished method18 by introducing green fluorescent coumarin 6 
loaded onto PGG-PTX. Cellular internalization of coumarin 
6-loaded PGG-PTX was examined in a model of human 
nonsmall cell lung cancer cells (NCI-H460). NCI-H460 
cell lines were incubated with 5 mg/mL of the fluorescent 
coumarin 6-loaded PGG-PTX, under cell culture conditions 
for 30 minutes and 4 hours of incubation time. After wash-
ing, the cells with green fluorescence were visualized using 
a fluorescence microscope system, and their images were 
captured. Double fluorescence-labeling experiments of green 
fluorescence from coumarin 6 and blue fluorescence from 
filtration, and might be effective carriers for drugs targeted 
to cancer tissues.
The physical stability of PGG-PTX in lyophilized form 
was evaluated at 4°C and room temperature to determine 
the stability of the ester linkage between the drug and 
polymer backbone by size exclusion high-pressure liquid 
chromatography and dynamic light scattering. A 90-day 
study concluded that lyophilized PGG-PTX could be 
stored for at least three months, with less than 2% and 5% 
release of free paclitaxel at 4°C and at room temperature, 
respectively (Figure 4A), without any significant change 
in its nanoparticle size in solution (Figure 4B). The same 
results were seen for PGG-PTX stored for two years at 4°C 
(data not shown). The stability of PGG-PTX as well as the 
high water solubility of its PGG backbone provides a good 
platform for poorly soluble aqueous drugs.
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Figure 7 cells were seeded in 96-well cell culture plates overnight before exposure to poly(l-γ-glutamylglutamine)-paclitaxel at a concentration range of 0.01–10 mg/mL. 
Incubation continued for (A) 48 hours and (B) 72 hours before MTs staining. survival of treated cells compared with untreated controls at each time point is shown.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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DAPI selectively labeling the nucleus were performed. As 
shown in Figure 5, the green fluorescent cells were observed 
after 30 minutes and 4 hours of incubation with the PGG-
PTX nanoparticles, which were seen to have penetrated the 
H460 cells. The images in the left column show the green 
fluorescence of the coumarin 6-loaded nanoparticles; the 
images in the right column show merged green fluorescence, 
and the blue fluorescence represents the nucleus stained 
by DAPI, which is circumscribed by green fluorescence 
representing the coumarin 6-loaded nanoparticles inter-
nalized in the cytoplasm. After 30 minutes, the coumarin 
6-loaded PGG-PTX nanoparticles were clearly taken up by 
the H460 cells.
To evaluate quantitatively the cellular uptake and kinetic 
internalization of the PGG-PTX nanoparticles further, the 
effects of various concentrations of coumarin 6-labeled 
PGG-PTX nanoparticles and different incubation times 
were investigated in two cell lines, ie, NCI-H460 and 
B16F0.15 The results are shown in Figure 6. After 4 hours 
of incubation, a concentration-dependent increase in the 
cell-associated fluorescence intensity was observed in both 
cell lines (Figure 6A). There was no statistically significant 
differences in cell-associated fluorescence between the 
NCI-H460 and B16F0 cells (P . 0.05). Notably, no differ-
ence in fluorescent intensity was observed at a PGG-PTX 
concentration of 5 mg/mL (paclitaxel equivalent) in either cell 
line from 30 minutes to 2 hours (Figure 6B). The intensity of 
cell-associated fluorescence in the B16F0 cell line was 52.0, 
41.9, and 41.9 for incubation times of 30 minutes, one hour, 
and 2 hours, respectively. A similar trend of fluorescent inten-
sity was seen for the NCI-H460 cells, ie, 39.0, 32.1, and 37.8, 
corresponding to incubation times of 30 minutes, 1 hour, and 
2 hours, respectively. However, a large increase in fluorescent 
intensity was observed between 2 and 4 hours of incubation 
time, ie, a 4.4-fold and 3.8-fold increase in fluorescent inten-
sity for B16F0 and NCI-H460 cells, respectively. This unex-
pected increase in cellular uptake is still under   investigation. 
The mechanism of in vitro cellular uptake of PGG-PTX nano-
particles can be assumed to be carrier-mediated endocytosis 
due to the small size of the particles.25
The in vitro cytotoxicity of PGG-PTX was investigated 
in various cancer cell lines at a concentration range of 
0.01–10.0 mg/mL over 48 and 72 hours of incubation. The 
results are shown in Figure 7 and Table 1, and indicate that 
the concentration and duration of incubation of PGG-PTX 
has an impact on cell viability. For instance, the IC50 values 
of 36.6, 8.2, and 4.8 µg/mL for paclitaxel were equivalent 
to those of PGG-PTX determined after 48 hours of incuba-
tion with C6, A549 and HeLa cancer cells, whereas the 
IC50 values decreased significantly down to 1.1–1.9 µg/mL 
when PGG-PTX was incubated with the same cells for 
Table 1 Ic50 (µg/mL) of free paclitaxel and Pgg-paclitaxel in 
various cell lines
IC50 (μg/mL) value  
of paclitaxel
IC50 (μg/mL, PTX equivalent) 
value of PGG-PTX
48 hours 72 hours 48 hours 72 hours
c6 0.58 ± 0.17 0.08 ± 0.02   36.66 ± 5.82   1.14 ± 0.10
A549 0.12 ± 0.02 0.04 ± 0.02   8.28 ± 2.82   1.24 ± 0.10
heLa 0.22 ± 0.08 0.31 ± 0.15   4.79 ± 1.86   1.91 ± 0.87
caco-2 1.16 ± 0.21 0.92 ± 0.40 182.04 ± 53.61 13.73 ± 4.68
hepg2 1.26 ± 0.45 0.91 ± 0.26 420.98 ± 136.96 22.84 ± 4.42
B16F0 3.82 ± 1.77 0.52 ± 0.14 217.18 ± 57.86 93.88 ± 13.51
Note: The Ic50 values are shown as a mean ± standard deviation (n = 3). 
Abbreviations: Pgg, poly(L-γ-glutamylglutamine); PTX, paclitaxel.
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Figure 8 effects of poly(L-γ-glutamylglutamine)-paclitaxel conjugate and poly(L-γ-glutamylglutamine) on red blood cell aggregation in ph 7.4 phosphate-buffered solution. 
Note: The relative percentages of hemolysis are shown as the mean ± standard deviation (n = 3). 
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72 hours. The longer incubation time achieving more potency 
might reflect the time needed for the active paclitaxel to 
be released from the polymer conjugate. Thus, use of the 
paclitaxel-  conjugated compound for systemic delivery 
would be beneficial to avoid the toxicity associated with 
paclitaxel alone. In addition, it would take some time for the 
polymer-drug conjugate to reach tumor tissue, accumulate 
at the target site, and release active paclitaxel.
hemolysis and in vivo tissue 
biocompatibility
Hemolysis was used to investigate the interaction between 
the PGG-PTX nanoconjugate and erythrocytes in buffer at 
pH 7.4. The results are shown in Figure 8, illustrating that 
PGG-PTX was not hemolytic under these testing conditions. 
PGG-PTX did not seem to interact with erythrocytes at up to 
20 mg/mL of PGG-PTX in buffer at pH 7.4. However, the 
poly(L-γ-glutamylglutamine) backbone polymer seemed to 
aggregate with red blood cells even at a 1 mg/mL concentra-
tion of PGG-PTX (Figure 9). Furthermore, in order to verify 
whether the PGG-PTX conjugate impaired tissue function 
and morphology, the heart, liver, spleen, lung, kidney, brain, 
skin, and small intestine were evaluated for various micro-
scopic changes after 21 days of treatment with PGG-PTX at 
a dose of 350 mg/kg via tail vein injection in tumor-bearing 
mice. As shown in Figure 10, all tissues seemed to be normal 
after 21 days of treatment with PGG-PTX when compared 
with the control group receiving saline (data not shown), 
PLL (1 mg/mL)
PGG (1 mg/mL) PGG-paclitaxel (20 mg/mL)
D-phosphate-buffered solution
Figure 9 effects of Pgg-paclitaxel, Pgg, and PLL on red blood cell aggregation in 
ph 7.4 phosphate-buffered solution. 
Note: The results are representative of three independent experiments. 
Abbreviations: Pgg, poly(L-γ-glutamylglutamine); PLL, poly(L-lysine).
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Figure 10 h460 cells were injected into each shoulder of 6–8-week-old female athymic nude (nu/nu) mice. These mice were treated with a single intravenous injection of 
Pgg-PTX (350 mg/mL, paclitaxel equivalent) when tumor size reached an average volume of 100 mm3. Two mice were sacrificed after treatment, and sections of various tissues 
were examined by using hematoxylin and eosin staining. (A) heart, (B) liver, (C) spleen, (D) lung, (E) kidney, (F) brain, (G) skin, and (H) small intestine. 
Note: Magnification 100×. 
Abbreviations: Pgg, poly(L-γ-glutamylglutamine); PTX, paclitaxel.International Journal of Nanomedicine
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indicating that PGG-PTX is biocompatible and would not 
induce severe damage in patients after treatment.
Conclusion
Paclitaxel conjugated with a water-soluble polymeric   carrier 
seems to be a promising strategy to enhance the physi-
cochemical and biopharmaceutical properties of paclitaxel. 
The present PGG-PTX conjugate was characterized by high 
drug loading, high water solubility, long stability, and good 
biocompatibility. In view of the favorable physicochemical 
properties discussed in this paper, we are confident in 
advancing this conjugate to clinical development.
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